Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?

Area of Science:

• Urology
• Biochemistry
• Medical Diagnostics

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Predicting BPH progression is crucial for effective patient management.
• Urinary prostate-specific antigen (uPSA) is being investigated as a biomarker for BPH.

Purpose of the Study:

• To evaluate the utility of urinary prostate-specific antigen (uPSA) as a predictive parameter for benign prostatic hyperplasia (BPH) progression.
• To determine the correlation between uPSA levels and BPH indicators such as total prostate volume (TPV), prostate-specific antigen (PSA), and age.

Main Methods:

• uPSA was measured in 265 patients diagnosed with benign prostate conditions.
• Patients were categorized based on total prostate volume (TPV) and MTOPS study criteria (TPV, PSA, age).
• Statistical analyses were performed to assess correlations and differences in uPSA levels across groups.

Main Results:

• Significantly higher average uPSA values were observed in patients with larger TPV (255.5 ± 204.9 ng/mL) compared to smaller TPV (119.3 ± 124.5 ng/mL).
• uPSA levels showed a significant difference across non-progressive, intermediate, and progressive BPH groups (86.8, 166.6, and 274.9 ng/mL, respectively).
• A uPSA cutoff level of 150 ng/mL demonstrated 83% specificity and 67% sensitivity in distinguishing non-progressive from progressive BPH.

Conclusions:

• Urinary PSA levels reflect prostatic hormonal activity and correlate with TPV, PSA, and age.
• A uPSA level of 150 ng/mL serves as a valuable additional predictive marker for BPH progression.
• This finding supports the use of uPSA in clinical practice for better BPH management.